Category: Press Release
Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober
Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober VICTORIA, Seychelles, Dec. 08, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today released its October 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 –
Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows
LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs
Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows
LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients.
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients.